ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
March 26, 2024 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
March 15, 2024 20:01 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Reschedules Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
February 22, 2024 08:30 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call and Participation at the 36th Annual ROTH Conference in March 2024
February 20, 2024 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Announces Fourth Quarter and Fiscal Year 2023 Investor and Business Update Call & Participation at the 36th Annual ROTH Conference in March 2024
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
January 30, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Severe Indication 510(k) Submission Accepted for Review by the FDA
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
January 29, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
January 08, 2024 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, welcomes the adoption of...
Data Published by Cureus Journal of Medical Science Shows Successful Treatment of Obstructive Sleep Apnea with ProSomnus Precision Oral Appliance Devices
December 19, 2023 08:00 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, today announced the publication of a...
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
November 09, 2023 16:17 ET
|
ProSomnus Sleep Technologies, Inc.
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
ProSomnus Announces Third Quarter 2023 Investor Call and Business Update
October 31, 2023 16:05 ET
|
ProSomnus Sleep Technologies, Inc.
PLEASANTON, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea (“OSA”), will report its third quarter...